Uncategorized
First patient enrolled in EGP-437 trial
The first patient has been enrolled in a phase 2b clinical study of EGP-437 for cataract surgery, according to an EyeGate Pharmaceuticals press release. EGP-437 is a combination product candidate for the treatment of postoperative ocular inflammation and pain. The double-masked, randomized, placebo-controlled trial will enroll up to 100 patients and will be conducted at up to eight sites in the United States, the release said.